Attorney Docket No.: Q80589 AMENDMENT UNDER 37 C.F.R. § 1.111

U.S. Application No.: 10/811,385

AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions and listings of claims in the

application:

LISTING OF CLAIMS:

1-5. (canceled).

6. (currently amended): A reagent kit for detecting anti-phospholipid antibody,

comprising;

a first coagulation time reagent containing a first composition for coagulation ;and at

least one and an anti-phospholipid antibody capturing component selected from the group

consisting of antibodies, plasma, serum, and immunoglobulin, the anti-phospholipid antibody

capturing component derived from vertebrate animals other than human; and

a second coagulation time reagent containing a composition for coagulation in the

absence of antibodies, plasma, and immunoglobulin derived from vertebrate animals other than

human-the anti-phospholipid antibody capturing component.

7. (canceled).

8. (currently amended): The reagent kit for detecting anti-phospholipid antibody

according to claim 6, wherein the anti-phospholipid antibody is human lupus anticoagulant.

4

AMENDMENT UNDER 37 C.F.R. § 1.111 Attorney Docket No.: Q80589

U.S. Application No.: 10/811,385

9. (currently amended): The A reagent kit for detecting anti-phospholipid antibody

according to claim 6, wherein, comprising;

the a first coagulation time reagent which comprises a first preparatory reagent and a

second preparatory-reagent, and

the-a second coagulation time reagent which comprises a third preparatory reagent and a

fourth preparatory-reagent,

the first preparatory reagent containing phospholipids; at least one, an anti-phospholipid

antibody capturing component selected from the group consisting of antibodies, plasma, serum,

and immunoglobulin derived from vertebrate animals other than human; and at least one

component selected from the group consisting of activator, viper venom, and tissue factor, the

anti-phospholipid antibody capturing component derived from vertebrate animals other than

human,

the second preparatory-reagent containing calcium ions,

the third preparatory reagent containing phospholipids, and at least one component

selected from the group consisting of contacting factor activator, viper venom, and tissue factor

in the absence of the anti-phospholipid antibody capturing component, and

the fourth preparatory reagent containing calcium ions.

10-14. (canceled).

5

AMENDMENT UNDER 37 C.F.R. § 1.111 Attorney Docket No.: Q80589

U.S. Application No.: 10/811,385

15. (new) The reagent kit according to claim 9, wherein the first reagent contains the phospholipids, the anti-phospholipid antibody capturing component and the activator, the second reagent contains calcium ions, the third reagent contains the phospholipids and the activator, and the forth reagent contains calcium ions.

- 16. (new) The reagent kit according to claim 9, wherein the first reagent contains the phospholipids, the anti-phospholipid antibody capturing component and the viper venom, the second reagent contains calcium ions, the third reagent contains the phospholipids and the viper venom, and the forth reagent contains calcium ions.
- 17. (new) The reagent kit according to claim 9, wherein the first reagent contains the phospholipids, the anti-phospholipid antibody capturing component and the tissue factor, the second reagent contains calcium ions, the third reagent contains the phospholipids and the tissue factor, and the forth reagent contains calcium ions.
- 18. (new) The reagent kit according to claim 6, wherein the animals are selected from a mammal other than human and swine.
- 19. (new) The reagent kit according to claim 6, wherein the first and second compositions include calcium ions, phospholipids and at least one component selected from the group consisting of activator, viper venom and tissue factor.

AMENDMENT UNDER 37 C.F.R. § 1.111 Attorney Docket No.: Q80589

U.S. Application No.: 10/811,385

20. (new) The reagent kit according to claim 19, wherein the activator is at least one selected from the group consisting of ellagic acid, kaolin, silica, and celite.

21. (new) A reagent kit for detecting anti-phospholipid antibody included in a sample, comprising;

a first coagulation time reagent containing a first composition for coagulation and an effective amount of an anti-phospholipid antibody capturing component selected from the group consisting of antibodies, plasma, serum and immunoglobulin, and the anti-phospholipid antibody capturing component derived from vertebrate animals other than human; and

a second coagulation time reagent containing a second composition for coagulation and not containing the effective amount of the anti-phospholipid antibody capturing component.

22. (new) A reagent kit for detecting anti-phospholipid antibody, comprising; a first coagulation time reagent which comprises a first reagent and a second reagent, and a second coagulation time reagent which comprises a third reagent and a fourth reagent, the first reagent containing phospholipids, an effective amount of an anti-phospholipid antibody capturing component selected from the group consisting of antibodies, plasma, serum and immunoglobulin, and at least one component selected from the group consisting of activator, viper venom and tissue factor, the anti-phospholipid antibody capturing component derived from vertebrate animals other than human,

AMENDMENT UNDER 37 C.F.R. § 1.111 U.S. Application No.: 10/811,385 Attorney Docket No.: Q80589

the second reagent containing calcium ions,

the third reagent containing phospholipids and at least one component selected from the group consisting of activator, viper venom and tissue factor, and not containing the effective amount of the anti-phospholipid antibody capturing component, and

the fourth reagent containing calcium ions.